Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niacin + simvastatin
- Development stage
- Unknown
- Lead developer
- University of Pennsylvania
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Niacin + simvastatin is a combination pharmacological regimen consisting of the lipid-lowering agent simvastatin and an extended-release formulation of niacin (nicotinic acid). This specific combination was the focus of the CARMA (Carotid Atherosclerosis Regression at Magnetic Resonance Assessment) study conducted at the University of Pennsylvania. Simvastatin is a small molecule HMG-CoA reductase inhibitor that reduces LDL cholesterol by blocking the rate-limiting step of cholesterol biosynthesis in the liver. Niacin acts through multiple pathways, including the activation of the G protein-coupled receptor GPR109A and the inhibition of diacylglycerol acyltransferase-2 (DGAT2), to increase HDL cholesterol levels and further reduce LDL and triglycerides. The combination therapy is designed to provide synergistic lipid modification to induce the regression of atherosclerotic plaques in patients with carotid artery disease.
- Brand names
- SimcorNiaspanZocor
- Other names
- nicotinic acid + simvastatinextended-release niacin + simvastatinNiaspan + simvastatin
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on niacin + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niacin + simvastatin.